Investegate |Destiny Pharma PLC Announcements | Destiny Pharma PLC: Director/PDMR Shareholding investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Investegate |Destiny Pharma PLC Announcements | Destiny Pharma PLC: XF-73 Phase 2b data to be presented at ECCMID investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Brighton, United Kingdom - 19 May 2021 - Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, as announced on 4 May 2021, will hold its 2021 Annual General Meeting ( AGM ) at the offices of finnCap Ltd, Destiny Pharma s Nominated Advisor and Joint Broker, at 11.00am BST on 3 June 2021. Destiny Pharma will operate an audio dial-in facility to allow Shareholders to listen to the business of the meeting.
As previously announced in the Posting of Annual Report and Notice of AGM, whilst in normal circumstances the Board values the opportunity to engage with shareholders in person at its AGM, on this occasion the Board feels it is appropriate to advise shareholders against travelling to attend the AGM in person and, instead, to submit proxy votes as early as possible because, as matters currently stand, shareholders will not be granted access to the AGM. Shareholders are strongly advised to appoint the Chairman of the AGM as their proxy.
Investegate |Destiny Pharma PLC Announcements | Destiny Pharma PLC: Destiny Pharma Announces Agreement with NIAID investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.